JPMorgan raised the firm’s price target on Teva (TEVA) to $26 from $23 and keeps an Overweight rating on the shares as part of a Q3 earnings preview. The firm expects no surprises in the quarter.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Teva put volume heavy and directionally bearish
- Teva Pharmaceutical: Strategic Focus and Financial Stability Drive Buy Rating
- Teva price target raised to $26 from $23 at UBS
- Teva announces presentation of data from survey of patients taking AUSTEDO XR
- Teva preesents 10 posters from its schizophrenia medicines portfolio